Information Provided By: 
Fly News Breaks for January 25, 2018
HOLX
Jan 25, 2018 | 10:23 EDT
Piper Jaffray analyst William Quirk says FDA approval of Hologic's Hepatitis B viral load assay rounds out the company's viral approvals in the U.S. HBV is the lowest volume of the three assays, but critical to Hologic gaining share of the $500M U.S. market as labs historically are resistant to change vendors without all three approvals, Quirk tells investors in a research note. He believes Hologic could transform the market and reiterates an Overweight rating on the shares with a $51 price target.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
